EGFR and non-small cell lung carcinoma: While another second‐generation EGFR TKI dacomitinib, a pan‐HER inhibitor, demonstrated its advantages over gefitinib in median PFS (14.7 vs. 9.2 months; HR, 0.59; 95%CI: 0.47, 0.74; p < 0.0001) and median OS (34.1 vs. 26.8 months; HR, 0.76; 95%CI: 0.58, 0.99; p = 0.04), was also approved for first‐line treatment for NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutations.143, 144